
## Andrew T Stefka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6057075/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood, 2020, 136, 2513-2523.	1.4	56
2	Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer Journal, 2021, 11, 19.	6.2	40
3	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2016, 128, 675-675.	1.4	38
4	Potent antiâ€myeloma activity of the TOPK inhibitor OTS514 in preâ€clinical models. Cancer Medicine, 2020, 9, 324-334.	2.8	14
5	Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT Journal of Clinical Oncology, 2020, 38, 8513-8513.	1.6	5